125742 45 S211 M5 c4591001 A 6mth report cci any malignancy 06aug2021
Document text
CCI_Any malignancy MedDRA Dictionary Version: 240 Status: ACTIVE Term Name: CCI_Any malignancy Code: 90002950 Extension: CCI Report Date/Time: 06-Aug-2021:02:13:04 PM EDT Term Code Level Category Weight Scope Small cell carcinoma of the cervix 10041057 PT Small cell carcinoma 10041056 PT Signet-ring cell carcinoma 10057266 PT Serous cystadenocarcinoma ovary 10054913 PT Cystadenocarcinoma pancreas 10065908 PT Seminoma 10039956 PT Secretory adenoma of pituitary 10039893 PT Second primary malignancy 10039801 PT Scrotal cancer 10039744 PT Sarcomatosis 10039500 PT Breast cancer stage IV 10006202 PT Breast cancer stage III 10006201 PT Breast cancer stage II 10006200 PT Breast cancer stage I 10006199 PT Breast cancer recurrent 10006198 PT Breast cancer male 10061020 PT Breast cancer in situ 10006189 PT Gastric cancer stage II 10017764 PT Gastric cancer stage I 10017763 PT Gastric cancer stage 0 10017762 PT Gastric cancer recurrent 10017761 PT Gastric cancer 10017758 PT Ganglioneuroblastoma 10017708 PT Ganglioglioma 10017701 PT Gallbladder squamous cell carcinoma 10073068 PT Gallbladder cancer stage IV 10058283 PT Gallbladder cancer stage III 10058282 PT Gallbladder cancer stage II 10058281 PT Gallbladder cancer stage I 10059317 PT Gallbladder cancer stage 0 10059316 PT Gallbladder cancer recurrent 10017619 PT Gallbladder cancer 10017614 PT 090177e198d54486\Final\Final On: 10-Dec-2021 02:59 (GMT) FDA-CBER-2022-5812-0219759 Gallbladder adenosquamous carcinoma 10073067 PT Gallbladder adenocarcinoma 10058286 PT Follicular thyroid cancer 10016935 PT Follicular dendritic cell sarcoma 10075332 PT Fibrosarcoma 10016632 PT Female reproductive tract carcinoma in situ 10061154 PT Fallopian tube cancer stage IV 10016187 PT Fallopian tube cancer stage III 10016186 PT Fallopian tube cancer stage II 10016185 PT Fallopian tube cancer stage I 10016184 PT Fallopian tube cancer 10016180 PT Extraskeletal osteosarcoma recurrent 10015852 PT Extraskeletal osteosarcoma 10015847 PT Extraskeletal myxoid chondrosarcoma 10073134 PT Extraskeletal chondrosarcoma recurrent 10015843 PT Extra-osseous Ewing's sarcoma recurrent 10015764 PT Extra-osseous Ewing's sarcoma 10015759 PT Extraocular retinoblastoma 10015831 PT Extragonadal primary seminoma (pure) stage IV 10015816 PT Extragonadal primary seminoma (pure) stage III 10015815 PT Extragonadal primary seminoma (pure) stage II 10015812 PT Intraocular melanoma 10061252 PT Intraductal proliferative breast lesion 10073094 PT Intraductal papillary-mucinous carcinoma of pancreas 10073365 PT Intracranial meningioma malignant 10022770 PT Intracranial germ cell tumour 10073751 PT Intestinal adenocarcinoma 10051925 PT Inflammatory malignant fibrous histiocytoma 10073142 PT Ovarian germ cell embryonal carcinoma stage I 10033196 PT Ovarian germ cell choriocarcinoma stage IV 10033195 PT Ovarian germ cell choriocarcinoma stage III 10033191 PT Ovarian germ cell choriocarcinoma stage II 10033187 PT Ovarian germ cell choriocarcinoma stage I 10033183 PT Ovarian germ cell choriocarcinoma 10073262 PT Ovarian germ cell cancer stage IV 10061897 PT 090177e198d54486\Final\Final On: 10-Dec-2021 02:59 (GMT) FDA-CBER-2022-5812-0219760 Ovarian germ cell cancer stage III 10061896 PT Ovarian germ cell cancer stage II 10061895 PT Ovarian germ cell cancer stage I 10061894 PT Clear cell carcinoma of cervix 10074909 PT Choroid plexus carcinoma 10067478 PT Inflammatory carcinoma of breast recurrent 10021977 PT Immune reconstitution inflammatory syndrome associated Kaposi's sarcoma 10072796 PT Hypopharyngeal cancer stage IV 10021049 PT Hypopharyngeal cancer stage III 10021048 PT Hypopharyngeal cancer stage II 10021047 PT Hypopharyngeal cancer stage I 10021046 PT Hypopharyngeal cancer stage 0 10021045 PT Hypopharyngeal cancer recurrent 10021044 PT Hypopharyngeal cancer 10021042 PT Huerthle cell carcinoma 10066136 PT Hormone-refractory prostate cancer 10062904 PT Hormone-dependent prostate cancer 10071119 PT Hormone refractory breast cancer 10076935 PT Histiocytic sarcoma 10076876 PT Histiocytic medullary reticulosis 10068785 PT HER2 positive gastric cancer 10066896 PT HER2 positive breast cancer 10065430 PT Hepatocellular carcinoma 10073071 PT Hepatoblastoma recurrent 10019823 PT Hepatoblastoma 10062001 PT Hepatobiliary cancer in situ 10073074 PT Hepatobiliary cancer 10073073 PT Hepatic cancer stage IV 10059325 PT Hepatic cancer stage III 10059324 PT Hepatic cancer stage II 10059319 PT Hepatic cancer stage I 10059318 PT Hepatic cancer recurrent 10073070 PT Hepatic cancer 10073069 PT Hepatic angiosarcoma 10067388 PT Heavy chain disease 10019350 PT Head and neck cancer stage IV 10071536 PT Head and neck cancer stage III 10071537 PT Head and neck cancer stage II 10071538 PT Head and neck cancer stage I 10071539 PT Head and neck cancer 10067821 PT Haematological malignancy 10066476 PT Haemangiopericytoma of meninges 10018826 PT Haemangiopericytoma 10018825 PT Glottis carcinoma 10018395 PT Gliosarcoma 10018340 PT Gliomatosis cerebri 10066254 PT Glioma 10018338 PT 090177e198d54486\Final\Final On: 10-Dec-2021 02:59 (GMT) FDA-CBER-2022-5812-0219761 Glioblastoma multiforme 10018337 PT Choroid melanoma 10008773 PT Choriocarcinoma 10008757 PT Chordoma 10008747 PT Chondrosarcoma recurrent 10008738 PT Chondrosarcoma 10008734 PT Cholangiosarcoma 10077861 PT Cholangiocarcinoma 10008593 PT Cervix carcinoma stage IV 10008348 PT Cervix carcinoma stage III 10008347 PT Cervix carcinoma stage II 10008346 PT Cervix carcinoma stage I 10008345 PT Cervix carcinoma stage 0 10061809 PT Cervix carcinoma recurrent 10008344 PT Cervix carcinoma 10008342 PT Central nervous system neuroblastoma 10073130 PT Central nervous system melanoma 10077160 PT Cardiac teratoma 10057456 PT Cardiac neoplasm malignant 10061025 PT Carcinoma in situ of trachea 10007401 PT Carcinoma in situ of penis 10007384 PT Carcinoma in situ of eye 10007368 PT Carcinoma in situ 10061450 PT Carcinoma ex-pleomorphic adenoma 10077435 PT Cancer in remission 10065305 PT Bronchioloalveolar carcinoma 10058354 PT Bronchial carcinoma 10006417 PT Breast sarcoma recurrent 10068584 PT Breast sarcoma 10068582 PT Renal cancer recurrent 10038390 PT Renal cancer 10038389 PT Refractory cancer 10070308 PT Recurrent cancer 10038111 PT Rectosigmoid cancer stage IV 10038099 PT Rectosigmoid cancer stage III 10038098 PT Rectosigmoid cancer stage II 10038097 PT Rectosigmoid cancer stage I 10038096 PT Erythroplasia of lip 10052826 PT Erythroblastosis 10049466 PT Epithelioid sarcoma recurrent 10015104 PT Epithelioid sarcoma 10015099 PT Epithelioid mesothelioma 10073064 PT Epiglottic cancer 10084056 PT Epididymal cancer 10073115 PT Ependymoma malignant 10014968 PT Ependymoma 10014967 PT Endotheliomatosis 10076868 PT Endometrial stromal sarcoma 10048397 PT Endometrial sarcoma recurrent 10067064 PT 090177e198d54486\Final\Final On: 10-Dec-2021 02:59 (GMT) FDA-CBER-2022-5812-0219762 Endometrial sarcoma 10057649 PT Endometrial cancer stage IV 10014741 PT Endometrial cancer stage III 10014740 PT Endometrial cancer stage II 10014739 PT Endometrial cancer stage I 10014738 PT Endometrial cancer stage 0 10014737 PT Endometrial cancer recurrent 10014736 PT Endometrial cancer 10014733 PT Endometrial adenocarcinoma 10014720 PT Endocrine neoplasm malignant 10061122 PT Embryonal rhabdomyosarcoma 10065868 PT Ear neoplasm malignant 10055017 PT Ductal adenocarcinoma of pancreas 10073364 PT Desmoplastic small round cell tumour 10064581 PT Desmoplastic mesothelioma 10073063 PT Dermatofibrosarcoma protuberans 10057070 PT Dedifferentiated liposarcoma 10073135 PT Cystadenocarcinoma ovary 10054912 PT Craniopharyngioma 10011318 PT Conjunctival primary acquired melanosis 10066925 PT Conjunctival melanoma 10066384 PT Colorectal carcinoma stage 0 10010038 PT Colorectal cancer stage IV 10010035 PT Colorectal cancer stage III 10010034 PT Colorectal cancer stage II 10010033 PT Colorectal cancer stage I 10010032 PT Colorectal cancer recurrent 10010030 PT Colorectal cancer 10061451 PT Colorectal adenocarcinoma 10052360 PT Colon cancer stage IV 10009956 PT Colon cancer stage III 10009955 PT Colon cancer stage II 10009954 PT Colon cancer stage I 10009953 PT Transitional cell carcinoma 10044412 PT Transitional cell cancer of the renal pelvis and ureter regional 10044411 PT Transitional cell cancer of the renal pelvis and ureter recurrent 10044410 PT Lip and/or oral cavity cancer 10061523 PT Linitis plastica 10024520 PT Light chain disease 10024459 PT Leptomeningeal myelomatosis 10078282 PT Leiomyosarcoma recurrent 10024194 PT Leiomyosarcoma 10024189 PT Transitional cell cancer of the renal pelvis and ureter localised 10044408 PT Transitional cell cancer of the renal pelvis and ureter 10044407 PT 090177e198d54486\Final\Final On: 10-Dec-2021 02:59 (GMT) FDA-CBER-2022-5812-0219763 Tracheal cancer 10044285 PT Tonsil cancer 10044002 PT Tongue neoplasm malignant stage unspecified 10043966 PT Tongue carcinoma stage IV 10058433 PT Tongue carcinoma stage III 10058432 PT Tongue carcinoma stage II 10058431 PT Tongue carcinoma stage I 10058430 PT Tongue carcinoma stage 0 10058429 PT Tongue cancer recurrent 10071251 PT Thyroid cancer stage IV 10071030 PT Thyroid cancer stage III 10071029 PT Thyroid cancer stage II 10071028 PT Thyroid cancer stage I 10071027 PT Thyroid cancer stage 0 10070567 PT Thyroid cancer recurrent 10072162 PT Thyroid cancer 10066474 PT Thymoma malignant recurrent 10043674 PT Thymoma malignant 10061031 PT Throat cancer 10043515 PT Testis cancer recurrent 10069813 PT Testis cancer 10057644 PT Testicular yolk sac tumour stage III 10043359 PT Testicular yolk sac tumour stage II 10043358 PT Neuroendocrine carcinoma of the bladder 10078341 PT Neuroendocrine carcinoma 10057270 PT Neuroblastoma recurrent 10066595 PT Neuroblastoma 10029260 PT Nephroblastoma 10029145 PT Neoplasm malignant 10028997 PT Nasopharyngeal cancer stage IV 10028792 PT Nasopharyngeal cancer stage III 10028791 PT Nasopharyngeal cancer stage II 10028790 PT Nasopharyngeal cancer stage I 10028789 PT Nasopharyngeal cancer stage 0 10028788 PT Nasopharyngeal cancer recurrent 10028787 PT Nasopharyngeal cancer 10061306 PT Nasal sinus cancer 10028767 PT Nasal cavity cancer 10028729 PT Myxoid liposarcoma 10073137 PT Myxofibrosarcoma 10066948 PT Myelofibrosis 10028537 PT Myeloblastoma 10051141 PT Musculoskeletal cancer 10077675 PT Multiple endocrine neoplasia Type 2 10073149 PT Mueller's mixed tumour 10066057 PT Mucoepidermoid carcinoma of salivary gland 10073371 PT Mucoepidermoid carcinoma 10057269 PT 090177e198d54486\Final\Final On: 10-Dec-2021 02:59 (GMT) FDA-CBER-2022-5812-0219764 Mucinous endometrial carcinoma 10028076 PT Colon cancer stage 0 10063523 PT Colon cancer recurrent 10009952 PT Colon cancer 10009944 PT CNS germinoma 10065852 PT Clear cell sarcoma of the kidney 10009253 PT Clear cell sarcoma of soft tissue 10073140 PT Clear cell renal cell carcinoma 10073251 PT Clear cell endometrial carcinoma 10009252 PT Papillary serous endo metrial carcinoma 10033700 PT Papillary renal cell carcinoma 10078493 PT Pancreatoblastoma 10073367 PT Pancreatic sarcoma 10055006 PT Pancreatic carcinoma stage IV 10059326 PT Pancreatic carcinoma stage III 10059323 PT Pancreatic carcinoma stage II 10059322 PT Pancreatic carcinoma stage I 10059321 PT Pancreatic carcinoma stage 0 10059320 PT Pancreatic carcinoma recurrent 10033613 PT Pancreatic carcinoma 10033609 PT Pancoast's tumour 10033572 PT Paget's disease of the vulva 10033369 PT Paget's disease of penis 10033365 PT Paget's disease of nipple 10033364 PT Ovarian stromal cancer 10065858 PT Ovarian low malignan t potential tumour 10033268 PT Ovarian germ cell tumour mixed 10073259 PT Ovarian germ cell teratoma stage IV 10033249 PT Ovarian germ cell teratoma stage III 10033245 PT Ovarian germ cell teratoma stage II 10033241 PT Ovarian germ cell teratoma stage I 10033237 PT Ovarian germ cell teratoma 10073265 PT Ovarian germ cell polyembryoma stage IV 10033235 PT Ovarian germ cell po lyembryoma stage III 10033231 PT Ovarian germ cell polyembryoma stage II 10033227 PT Ovarian germ cell polyembryoma stage I 10033223 PT Ovarian germ cell polyembryoma 10073264 PT Ovarian germ cell endodermal sinus tumour stage IV 10033221 PT Ovarian germ cell endodermal sinus tumour stage III 10033220 PT Ovarian germ cell endodermal sinus tumour stage II 10033219 PT 090177e198d54486\Final\Final On: 10-Dec-2021 02:59 (GMT) FDA-CBER-2022-5812-0219765 Ovarian germ cell endodermal sinus tumour stage I 10033218 PT Ovarian germ cell endodermal sinus tumour 10073263 PT Ovarian germ cell embryonal carcinoma stage IV 10033208 PT Ovarian germ cell embryonal carcinoma stage III 10033204 PT Ovarian germ cell embryonal carcinoma stage II 10033200 PT Mesothelioma malignant recurrent 10027411 PT Mesothelioma malignant 10027407 PT Meningioma malignant 10027193 PT Medulloblastoma recurrent 10066594 PT Medulloblastoma 10027107 PT Medullary thyroid cancer 10027105 PT Medullary carcinoma of breast 10027095 PT Malignant urinary tract neoplasm 10061272 PT Malignant transformation 10064912 PT Malignant splenic neoplasm 10026702 PT Testicular yolk sac tumour stage I 10043357 PT Testicular yolk sac tumour 10073121 PT Testicular seminoma (pure) stage III 10043352 PT Testicular seminoma (pure) stage II 10043351 PT Testicular seminoma (pure) stage I 10043350 PT Testicular seminoma (pure) 10062124 PT Testicular malignant teratoma stage III 10043341 PT Testicular malignant teratoma stage II 10043340 PT Testicular malignant teratoma stage I 10043339 PT Testicular malignant teratoma 10073120 PT Glioblastoma 10018336 PT Gingival cancer 10067807 PT Germ cell cancer 10061184 PT Genitourinary melanoma 10077166 PT Genital neoplasm malignant female 10018160 PT Genital cancer male in situ 10073124 PT Genital cancer male 10073116 PT Gastrooesophageal cancer 10062878 PT Gastrointestinal stromal tumour 10051066 PT Gastrointestinal melanoma 10077167 PT Gastrointestinal carcinoma in situ 10061168 PT Gastrointestinal carcinoma 10017940 PT Gastrinoma malignant 10051709 PT Gastric sarcoma 10055008 PT Iris melanoma 10073086 PT Invasive papillary breast carcinoma 10073098 PT Invasive lobular breast carcinoma 10073096 PT Invasive ductal breast carcinoma 10073095 PT Invasive breast carcinoma 10075713 PT 090177e198d54486\Final\Final On: 10-Dec-2021 02:59 (GMT) FDA-CBER-2022-5812-0219766 Intraosseous angioma 10048846 PT Extragonadal primary seminoma (pure) stage I 10015811 PT Extragonadal primary seminoma (pure) 10073057 PT Extragonadal primary non-seminoma stage IV 10015810 PT Extragonadal primary non-seminoma stage III 10015809 PT Extragonadal primary non-seminoma stage II 10015806 PT Extragonadal primary non-seminoma stage I 10015805 PT Extragonadal primary non-seminoma 10061849 PT Testicular leiomyosarcoma 10057340 PT Testicular germ cell tumour mixed stage III 10043333 PT Testicular germ cell tumour mixed stage II 10043332 PT Testicular germ cell tumour mixed stage I 10043331 PT Testicular germ cell tumour mixed 10073119 PT Testicular germ cell cancer 10061378 PT Testicular embryonal carcinoma stage III 10043311 PT Testicular embryonal carcinoma stage II 10043310 PT Testicular embryonal carcinoma stage I 10043309 PT Testicular embryonal carcinoma 10062123 PT Testicular choriocarcinoma stage III 10043305 PT Testicular choriocarcinoma stage II 10043304 PT Testicular choriocarcinoma stage I 10043303 PT Testicular choriocarcinoma recurrent 10069812 PT Testicular choriocarcinoma 10062122 PT Synovial sarcoma recurrent 10042867 PT Synovial sarcoma 10042863 PT Stewart-Treves syndrome 10059498 PT Squamous endometrial carcinoma 10041883 PT Squamous cell carcinoma of the vulva 10041875 PT Squamous cell carcinoma of the vagina 10041866 PT Squamous cell carcinoma of the tongue 10041865 PT Squamous cell carcinoma of the oral cavity 10041857 PT Squamous cell carcinoma of the hypopharynx 10041849 PT Squamous cell carcinoma of the cervix 10041848 PT 090177e198d54486\Final\Final On: 10-Dec-2021 02:59 (GMT) FDA-CBER-2022-5812-0219767 Squamous cell carcinoma of pharynx 10066471 PT Squamous cell carcinoma of lung 10041826 PT Squamous cell carcinoma of head and neck 10060121 PT Spindle cell sarcoma 10049067 PT Spinal meningioma malignant 10041580 PT Spermatocytic seminoma 10073118 PT Somatostatinoma 10041329 PT Solid pseudopapillary tumour of the pancreas 10069345 PT Soft tissue sarcoma 10075333 PT Small intestine leiomyosarcoma 10041127 PT Small intestine carcinoma stage IV 10059372 PT Small intestine carcinoma stage III 10059371 PT Small intestine carcinoma stage II 10059370 PT Small intestine carcinoma stage I 10059369 PT Small intestine carcinoma stage 0 10059368 PT Small intestine carcinoma recurrent 10041124 PT Small intestine carcinoma 10054184 PT Small intestine adenocarcinoma 10073373 PT Small cell lung cancer recurrent 10041070 PT Small cell lung cancer limited stage 10041069 PT Small cell lung cancer extensive stage 10041068 PT Small cell lung cancer 10041067 PT Gastric cancer stage IV 10061967 PT Gastric cancer stage III 10017765 PT Ovarian dysgerminoma stage unspecified 10052759 PT Ovarian dysgerminoma stage IV 10033156 PT Ovarian dysgerminoma stage III 10033152 PT Ovarian dysgerminoma stage II 10033148 PT Ovarian dysgerminoma stage I 10033144 PT Ovarian clear cell carcinoma 10073268 PT Ovarian cancer stage IV 10070908 PT Ovarian cancer stage III 10070907 PT Ovarian cancer stage II 10070906 PT Ovarian cancer stage I 10070905 PT Ovarian cancer recurrent 10066697 PT Ovarian cancer 10033128 PT Osteosarcoma recurrent 10031296 PT Osteosarcoma 10031291 PT Oropharyngeal squamous cell carcinoma 10031112 PT Oropharyngeal lymphoepithelioma 10031104 PT Oropharyngeal cancer stage IV 10064099 PT Oropharyngeal cancer stage III 10031102 PT Oropharyngeal cancer stage II 10031101 PT Oropharyngeal cancer stage I 10031100 PT Oropharyngeal cancer stage 0 10031099 PT Oropharyngeal cancer recurrent 10031098 PT 090177e198d54486\Final\Final On: 10-Dec-2021 02:59 (GMT) FDA-CBER-2022-5812-0219768 Oropharyngeal cancer 10031096 PT Optic glioma 10073338 PT Oligodendroglioma 10030286 PT Oligoastrocytoma 10073131 PT Hormone receptor positive breast cancer 10083234 PT Oesophageal squamous cell carcinoma stage IV 10030192 PT Oesophageal squamous cell carcinoma stage III 10030191 PT Oesophageal squamous cell carcinoma stage II 10030190 PT Oesophageal squamous cell carcinoma stage I 10030189 PT Oesophageal squamous cell carcinoma stage 0 10030188 PT Oesophageal squamous cell carcinoma recurrent 10030187 PT Oesophageal squamous cell carcinoma 10061534 PT Oesophageal carcinoma stage 0 10030162 PT Oesophageal carcinoma recurrent 10030159 PT Oesophageal carcinoma 10030155 PT Oesophageal adenoca rcinoma stage IV 10030145 PT Oesophageal adenoca rcinoma stage III 10030144 PT Oesophageal adenoca rcinoma stage II 10030143 PT Oesophageal adenoca rcinoma stage I 10030142 PT Oesophageal adenoca rcinoma stage 0 10030141 PT Oesophageal adenocarcinoma recurrent 10030140 PT Oesophageal adenocarcinoma 10030137 PT Ocular haemangiopericytoma 10057416 PT NUT midline carcinoma 10078295 PT Non-small cell lung cancer stage IV 10029522 PT Non-small cell lung cancer stage IIIB 10029521 PT Non-small cell lung cancer stage IIIA 10029520 PT Non-small cell lung cancer stage III 10029519 PT Non-small cell lung cancer stage II 10029518 PT Non-small cell lung cancer stage I 10029517 PT Non-small cell lung cancer stage 0 10029516 PT Non-small cell lung cancer recurrent 10029515 PT Non-small cell lung cancer 10061873 PT Non-secretory adenoma of pituitary 10029556 PT Non-renal cell carcinoma of kidney 10061872 PT Nonkeratinising carcinoma of nasopharynx 10073325 PT 090177e198d54486\Final\Final On: 10-Dec-2021 02:59 (GMT) FDA-CBER-2022-5812-0219769 Nongerminomatous germ cell tumour of the CNS 10065871 PT Neurofibrosarcoma recurrent 10029277 PT Malignant giant cell fibrous histiocytoma 10073141 PT Malignant genitourinary tract neoplasm 10074419 PT Malignant fibrous his tiocytoma recurrent 10025561 PT Malignant fibrous histiocytoma of bone 10025557 PT Malignant fibrous histiocytoma 10025552 PT Malignant cranial nerve neoplasm 10061238 PT Malignant connective tissue neoplasm 10074340 PT Malignant anorectal neoplasm 10061237 PT Lymphangiosarcoma 10025223 PT Lung squamous cell carcinoma stage IV 10025125 PT Lung squamous cell ca rcinoma stage III 10025124 PT Lung squamous cell carcinoma stage II 10025123 PT Lung squamous cell carcinoma stage I 10025122 PT Lung squamous cell carcinoma stage 0 10025121 PT Lung squamous cell carcinoma recurrent 10025120 PT Lung neoplasm malignant 10058467 PT Lung infiltration malignant 10062041 PT Lung carcinoma cell type unspecified stage IV 10025070 PT Lung carcinoma cell type unspecified stage III 10025069 PT Lung carcinoma cell type unspecified stage II 10025068 PT Lung carcinoma cell type unspecified stage I 10025067 PT Lung carcinoma cell type unspecified stage 0 10025066 PT Lung carcinoma cell type unspecified recurrent 10025065 PT Lung adenocarcinoma stage IV 10025038 PT Lung adenocarcinoma stage III 10025037 PT Lung adenocarcinoma stage II 10025036 PT Lung adenocarcinoma stage I 10025035 PT Lung adenocarcinoma stage 0 10025034 PT Lung adenocarcinoma recurrent 10025033 PT Lung adenocarcinoma 10025031 PT Lobular breast carcinoma in situ 10073099 PT Liver carcinoma ruptured 10050842 PT 090177e198d54486\Final\Final On: 10-Dec-2021 02:59 (GMT) FDA-CBER-2022-5812-0219770 Liposarcoma recurrent 10024632 PT Liposarcoma 10024627 PT Lip squamous cell carcinoma 10064055 PT Sarcomatoid mesothelioma 10073065 PT Sarcoma uterus 10039497 PT Sarcoma of skin 10039495 PT Sarcoma 10039491 PT Salivary gland cancer stage IV 10039403 PT Salivary gland cancer stage III 10039402 PT Salivary gland cancer stage II 10039401 PT Salivary gland cancer stage I 10039400 PT Salivary gland cancer stage 0 10039399 PT Salivary gland cancer recurrent 10039398 PT Salivary gland cancer 10061934 PT Round cell liposarcoma 10073139 PT Rhabdomyosarcoma recurrent 10039027 PT Rhabdomyosarcoma 10039022 PT Rhabdoid tumour of the kidney 10039019 PT Rhabdoid tumour 10073334 PT Retroperitoneal cancer 10038977 PT Retinoblastoma 10038916 PT Retinal melanoma 10038878 PT Respiratory tract carcinoma in situ 10038724 PT Renal cell carcinoma stage IV 10038414 PT Renal cell carcinoma stage III 10038413 PT Renal cell carcinoma stage II 10038412 PT Renal cell carcinoma stage I 10038411 PT Renal cell carcinoma recurrent 10038410 PT Renal cell carcinoma 10067946 PT Renal cancer stage IV 10038394 PT Renal cancer stage III 10038393 PT Renal cancer stage II 10038392 PT Renal cancer stage I 10038391 PT Inflammatory carcinoma of the breast 10021980 PT Inflammatory carcinoma of breast stage IV 10021979 PT Inflammatory carcinoma of breast stage III 10021978 PT Extragonadal primary malignant teratoma 10061848 PT Extragonadal primary embryonal carcinoma 10015789 PT Ewing's sarcoma recurrent 10015564 PT Ewing's sarcoma 10015560 PT Erythroplasia of vulva 10052825 PT Rectosigmoid cancer stage 0 10038095 PT Rectosigmoid cancer recurrent 10038094 PT Rectosigmoid cancer 10038086 PT Rectal cancer stage IV 10038051 PT Rectal cancer stage III 10038050 PT 090177e198d54486\Final\Final On: 10-Dec-2021 02:59 (GMT) FDA-CBER-2022-5812-0219771 Rectal cancer stage II 10038049 PT Rectal cancer stage I 10038048 PT Rectal cancer stage 0 10038047 PT Rectal cancer recurrent 10038046 PT Rectal cancer 10038038 PT Rectal adenocarcinoma 10038019 PT Prostate cancer stage IV 10036920 PT Prostate cancer stage III 10036919 PT Prostate cancer stage II 10036918 PT Prostate cancer stage I 10036917 PT Prostate cancer stage 0 10036912 PT Prostate cancer recurrent 10036911 PT Prostate cancer 10060862 PT Primitive neuroectodermal tumour 10057846 PT Mucinous cystadenocarcinoma ovary 10054914 PT Mucinous breast carcinoma 10073101 PT Mucinous adenocarcinoma of appendix 10073361 PT Mixed-type liposarcoma 10073136 PT Mixed hepatocellular cholangiocarcinoma 10027761 PT Mixed adenoneuroendocrine carcinoma 10076748 PT Metaplastic breast carcinoma 10073100 PT Laryngeal squamous cell carcinoma 10023856 PT Laryngeal cancer stage IV 10023833 PT Laryngeal cancer stage III 10023832 PT Laryngeal cancer stage II 10023831 PT Laryngeal cancer stage I 10023830 PT Laryngeal cancer stage 0 10023829 PT Laryngeal cancer recurrent 10023828 PT Laryngeal cancer 10023825 PT Large cell lung cancer stage IV 10023780 PT Large cell lung cancer stage III 10023779 PT Large cell lung cancer stage II 10023778 PT Large cell lung cancer stage I 10023777 PT Large cell lung cancer stage 0 10023776 PT Large cell lung cancer recurrent 10023775 PT Large cell lung cancer 10023774 PT Langerhans' cell histiocytosis 10069698 PT Keratinising squamous cell carcinoma of nasopharynx 10073324 PT Kaposi's sarcoma classical type 10023288 PT Kaposi's sarcoma 10023284 PT Adenosquamous cell lung cancer stage 0 10001248 PT Adenosquamous cell lung cancer recurrent 10001247 PT Adenosquamous cell lung cancer 10001245 PT Adenosquamous cell carcinoma 10068873 PT 090177e198d54486\Final\Final On: 10-Dec-2021 02:59 (GMT) FDA-CBER-2022-5812-0219772 Adenosquamous carcinoma of vagina 10073978 PT Adenosquamous carcinoma of the cervix 10001244 PT Adenoid cystic carcinoma of salivary gland 10073370 PT External ear neoplasm malignant 10082277 PT Adenoid cystic carcinoma 10053231 PT Adenocarcinoma pancreas 10052747 PT Adenocarcinoma of the cervix 10001197 PT Adenocarcinoma of salivary gland 10068068 PT Adenocarcinoma of colon 10001167 PT Adenocarcinoma of appendix 10073359 PT Adenocarcinoma gastric 10001150 PT Adenocarcinoma 10001141 PT Acinic cell carcinoma of salivary gland 10073369 PT Acinar cell carcinoma of pancreas 10073363 PT Abdominal wall neoplasm malignant 10071023 PT Yolk sac tumour site unspecified 10048251 PT Vulvar adenocarcinoma 10063536 PT Vulval cancer stage IV 10047749 PT Vulval cancer stage III 10047748 PT Vulval cancer stage II 10047747 PT Vulval cancer stage I 10047746 PT Vulval cancer stage 0 10047745 PT Vulval cancer recurrent 10047744 PT Vulval cancer 10047741 PT Vaginal cancer stage IVB 10046895 PT Vaginal cancer stage IVA 10046894 PT Vaginal cancer stage III 10046893 PT Vaginal cancer stage II 10046892 PT Vaginal cancer stage I 10046891 PT Vaginal cancer stage 0 10046890 PT Vaginal cancer recurrent 10046889 PT Vaginal cancer 10046885 PT Vaginal adenocarcinoma 10065349 PT Uterine carcinoma in situ 10046770 PT Uterine cancer 10046766 PT Urinary tract carcinoma in situ 10061396 PT Urinary bladder sarcoma 10051690 PT Urethral cancer recurrent 10046435 PT Urethral cancer 10046431 PT Ureteric cancer regional 10046397 PT Ureteric cancer recurrent 10046396 PT Ureteric cancer local 10046393 PT Malignant respiratory tract neoplasm 10061270 PT Malignant polyp 10078695 PT Malignant pituitary tumour 10026672 PT Malignant peritoneal neoplasm 10061269 PT Malignant pericardial neoplasm 10054946 PT Malignant palate neoplasm 10026663 PT 090177e198d54486\Final\Final On: 10-Dec-2021 02:59 (GMT) FDA-CBER-2022-5812-0219773 Malignant ovarian cyst 10026662 PT Malignant olig odendroglioma 10026659 PT Malignant nipple neoplasm male 10053128 PT Malignant nipple neoplasm female 10053129 PT Malignant nipple neoplasm 10062051 PT Malignant nervous system neoplasm 10061268 PT Malignant neoplasm progression 10051398 PT Malignant neoplasm papilla of Vater 10077303 PT Malignant neoplasm of uterine adnexa 10026616 PT Malignant neoplasm of unknown primary site 10073059 PT Malignant neoplasm of thymus 10026533 PT Malignant neoplasm of thorax 10026532 PT Malignant neoplasm of spinal cord 10026472 PT Malignant neoplasm of spermatic cord 10026470 PT Malignant neoplasm of seminal vesicle 10068124 PT Malignant neoplasm of retina 10026432 PT Lip neoplasm malignant stage unspecified 10024557 PT Lip and/or oral cavity cancer stage IV 10024540 PT Lip and/or oral cavity cancer stage III 10024539 PT Lip and/or oral cavity cancer stage II 10024538 PT Lip and/or oral cavity cancer stage I 10024537 PT Lip and/or oral cavity cancer stage 0 10024536 PT Lip and/or oral cavity cancer recurrent 10024535 PT Malignant neoplasm of renal pelvis 10026426 PT Malignant neoplasm of pleura 10026351 PT Malignant neoplasm of placenta 10026350 PT Malignant neoplasm of paraurethral glands 10026326 PT Malignant neoplasm of orbit 10026183 PT Malignant neoplasm of lacrimal gland 10026031 PT Malignant neoplasm of lacrimal duct 10026030 PT Malignant neoplasm of islets of Langerhans 10025997 PT Malignant neoplasm of eyelid 10063693 PT Malignant neoplasm of eye 10025910 PT Malignant neoplasm of cornea 10025871 PT Malignant neoplasm of conjunctiva 10025861 PT Malignant neoplasm of choroid 10025839 PT Malignant neoplasm of ampulla of Vater 10025697 PT Malignant muscle neoplasm 10062050 PT Malignant middle ear neoplasm 10061267 PT Malignant mesenteric neoplasm 10067369 PT Malignant mesenchymoma recurrent 10025677 PT 090177e198d54486\Final\Final On: 10-Dec-2021 02:59 (GMT) FDA-CBER-2022-5812-0219774 Malignant mesenchymoma 10061526 PT Malignant melanoma of sites other than skin 10025654 PT Malignant melanoma of eyelid 10063706 PT Malignant melanoma 10025650 PT Malignant mediastinal neoplasm 10061241 PT Malignant mast cell neoplasm 10025638 PT Malignant joint neoplasm 10078145 PT Malignant hydatidiform mole 10025598 PT Malignant histiocytosis 10025581 PT Malignant haemangiopericytoma recurrent 10025570 PT Malignant haemangiopericytoma 10025566 PT Malignant glioma 10065443 PT Penis carcinoma stage I 10034332 PT Penis carcinoma recurrent 10034331 PT Penile squamous cell carcinoma 10059631 PT Penile cancer 10034299 PT Parathyroid tumour malignant 10033965 PT Paranasal sinus and nasal cavity malignant neoplasm stage IV 10033860 PT Paranasal sinus and nasal cavity malignant neoplasm stage III 10033859 PT Paranasal sinus and nasal cavity malignant neoplasm stage II 10033858 PT Paranasal sinus and nasal cavity malignant neoplasm stage I 10033857 PT Paranasal sinus and nasal cavity malignant neoplasm stage 0 10033856 PT Paranasal sinus and nasal cavity malignant neoplasm recurrent 10033855 PT Paranasal sinus and nasal cavity malignant neoplasm 10061909 PT Paraganglion neoplasm malignant 10033791 PT Papillary thyroid cancer 10033701 PT Ureteric cancer 10046392 PT Undifferentiated sarcoma 10045515 PT Undifferentiated nasopharyngeal carcinoma 10073328 PT Undifferentiated carcinoma of colon 10073362 PT Tumour of ampulla of Vater 10073851 PT Tumour invasion 10064390 PT Tumour budding 10076969 PT Tubular breast carcinoma 10073104 PT Triple negative breast cancer 10075566 PT Transitional cell carcinoma urethra 10044426 PT Transitional cell carcinoma recurrent 10077051 PT Ovarian germ cell cancer 10061893 PT Ovarian epithelial cancer stage IV 10033164 PT Ovarian epithelial cancer stage III 10033163 PT 090177e198d54486\Final\Final On: 10-Dec-2021 02:59 (GMT) FDA-CBER-2022-5812-0219775 Ovarian epithelial cancer stage II 10033162 PT Ovarian epithelial cancer stage I 10033161 PT Ovarian epithelial cancer recurrent 10033160 PT Ovarian epithelial cancer 10061328 PT Ovarian endometrioid carcinoma 10073269 PT Ovarian embryonal carcinoma 10056266 PT Bile duct cancer stage 0 10059384 PT Bile duct cancer recurrent 10004596 PT Bile duct cancer 10004593 PT Bile duct adenosquamous carcinoma 10004589 PT Bile duct adenocarcinoma 10004585 PT Basosquamous carcinoma 10004178 PT Atypical teratoid/rhabdoid tumour of CNS 10065907 PT Astrocytoma malignant 10060971 PT Astrocytoma 10003571 PT APUDoma 10003069 PT Appendix cancer 10073360 PT Apocrine breast carcinoma 10066206 PT Angiosarcoma recurrent 10002480 PT Angiosarcoma non-metastatic 10057700 PT Angiosarcoma 10002476 PT Angiocentric glioma 10073129 PT Anaplastic thyroid cancer 10002240 PT Anaplastic oligodendroglioma 10073128 PT Anaplastic meningioma 10073127 PT Anaplastic astrocytoma 10002224 PT Anal squamous cell carcinoma 10073358 PT Anal cancer stage IV 10002138 PT Bladder adenocarcinoma stage II 10004989 PT Bladder adenocarcinoma stage I 10004988 PT Bladder adenocarcinoma stage 0 10004987 PT Bladder adenocarcinoma recurrent 10004986 PT Biphasic mesothelioma 10073062 PT Bile duct squamous cell carcinoma 10004633 PT Bile duct cancer stage IV 10059376 PT Bile duct cancer stage III 10059375 PT Bile duct cancer stage II 10059374 PT Bile duct cancer stage I 10059373 PT Postcricoid cancer 10036334 PT Poorly differentiated thyroid carcinoma 10076603 PT Polycythaemia vera 10036057 PT Pleural sarcoma 10051950 PT Pleural mesothelioma malignant recurrent 10035607 PT Pleural mesothelioma malignant 10059518 PT Pleural mesothelioma 10035603 PT Pleomorphic malignant fibrous histiocytoma 10073143 PT 090177e198d54486\Final\Final On: 10-Dec-2021 02:59 (GMT) FDA-CBER-2022-5812-0219776 Pleomorphic liposarcoma 10073138 PT Plasmacytoma 10035484 PT Plasma cell myeloma recurrent 10073133 PT Plasma cell myeloma in remission 10073132 PT Plasma cell myeloma 10035226 PT Pituitary neoplasm malignant recurrent 10057838 PT Pinealoblastoma 10050487 PT Anal cancer stage III 10002137 PT Anal cancer stage II 10002136 PT Anal cancer stage I 10002135 PT Anal cancer stage 0 10002134 PT Anal cancer recurrent 10002133 PT Anal cancer 10061424 PT Alveolar soft part sarcoma recurrent 10001887 PT Alveolar soft part sarcoma 10001882 PT Alveolar rhabdomyosarcoma 10065867 PT Aesthesioneuroblastoma 10001433 PT Adrenocortical carcinoma 10001388 PT Adrenal gland cancer 10073152 PT Adenosquamous cell lung cancer stage IV 10001254 PT Adenosquamous cell lung cancer stage III 10001251 PT Adenosquamous cell lung cancer stage II 10001250 PT Adenosquamous cell lung cancer stage I 10001249 PT Breast cancer female 10057654 PT Breast cancer 10006187 PT Breast angiosarcoma 10072813 PT Brain teratoma 10068394 PT Brain stem glioma 10006143 PT Brain sarcoma 10073857 PT Brain neoplasm malignant 10006131 PT Borderline serous tumour of ovary 10073267 PT Borderline ovarian tumour 10006032 PT Borderline mucinous tumour of ovary 10073266 PT Bone sarcoma 10006007 PT Bone marrow tumour cell infiltration 10049556 PT Bone giant cell tumour malignant 10073106 PT Bone cancer 10005949 PT Bladder transitional c ell carcinoma stage IV 10066752 PT Bladder transitional ce ll carcinoma stage III 10066754 PT Bladder transitional c ell carcinoma stage II 10066753 PT Bladder transitional c ell carcinoma stage I 10066751 PT 090177e198d54486\Final\Final On: 10-Dec-2021 02:59 (GMT) FDA-CBER-2022-5812-0219777 Bladder transitional c ell carcinoma stage 0 10066749 PT Bladder transitional cell carcinoma recurrent 10066750 PT Bladder transitional cell carcinoma 10005084 PT Bladder squamous ce ll carcinoma stage unspecified 10005081 PT Bladder squamous ce ll carcinoma stage IV 10005080 PT Bladder squamous cell carcinoma stage III 10005079 PT Bladder squamous ce ll carcinoma stage II 10005078 PT Bladder squamous ce ll carcinoma stage I 10005077 PT Bladder squamous ce ll carcinoma stage 0 10005076 PT Bladder squamous cell carcinoma recurrent 10005075 PT Bladder cancer stage IV 10005012 PT Bladder cancer stage III 10005011 PT Bladder cancer stage II 10005010 PT Bladder cancer stage I, without cancer in situ 10005009 PT Bladder cancer stage I, with cancer in situ 10005008 PT Bladder cancer stage 0, without cancer in situ 10005007 PT Bladder cancer stage 0, with cancer in situ 10005006 PT Bladder cancer recurrent 10005005 PT Bladder cancer 10005003 PT Bladder adenocarcinoma stage unspecified 10004992 PT Bladder adenocarcinoma stage IV 10004991 PT Bladder adenocarcinoma stage III 10004990 PT Pineal parenchymal neoplasm malignant 10061537 PT Pineal germinoma 10035052 PT Pharyngeal cancer stage IV 10034818 PT Pharyngeal cancer stage III 10034817 PT Pharyngeal cancer stage II 10034816 PT Pharyngeal cancer stage I 10034815 PT Pharyngeal cancer stage 0 10034814 PT Pharyngeal cancer recurrent 10034813 PT Pharyngeal cancer 10034811 PT Phaeochromocytoma malignant 10051710 PT Phaeochromocytoma crisis 10068778 PT Phaeochromocytoma 10034800 PT Peritoneal sarcoma 10051949 PT 090177e198d54486\Final\Final On: 10-Dec-2021 02:59 (GMT) FDA-CBER-2022-5812-0219778 Peritoneal mesothelioma malignant recurrent 10034671 PT Peritoneal mesothelioma malignant 10056558 PT Peritoneal gliomatosis 10070561 PT Peripheral primitive neuroectodermal tumour of soft tissue 10073144 PT Peripheral primitive neuroectodermal bone tumour 10073107 PT Peripheral neuroepithelioma of soft tissue 10057646 PT Peripheral neuroepithelioma of bone recurrent 10034605 PT Peripheral neuroepithelioma of bone 10061342 PT Neurofibrosarcoma 10061527 PT Pericardial mesothelioma malignant recurrent 10034480 PT Pericardial mesothelioma malignant 10073066 PT Penis carcinoma stage IV 10034335 PT Penis carcinoma stage III 10034334 PT Penis carcinoma stage II 10034333 PT 090177e198d54486\Final\Final On: 10-Dec-2021 02:59 (GMT) FDA-CBER-2022-5812-0219779